Latest News
BioStock article: Spotlight on MS
BioStock published an article on 28 May 2021 about Cyxone, which can be read in full below. World MS Day will be celebrated on Sunday May 30th. It is a day to raise awareness of the condition, and to...
Read MoreBioStock article: Cyxones expands possibilities for T20K in MS
BioStock published an article on 20 May 2021 about Cyxone, which can be read in full below. Recently, Malmö-based company Cyxone, announced the next development steps for its drug candidate T20K for the treatment of multiple sclerosis. A process...
Read MoreBioStock article: Cyxone joins forces with leading rheumatoid arthritis expert
BioStock published an article on 18 May 2021 about Cyxone, which can be read in full below. Biotech company Cyxone is in the process of preparing drug candidate Rabeximod for the next clinical stage. Recently, the company announced a...
Read MoreBioStock article: Progress in Q4 sets tone for Cyxone in 2021
BioStock published an article on 24 February 2021 about Cyxone, which can be read in full below. Biotech company Cyxone recently published its fourth quarter result, a period with great focus in the advancement of the project with the...
Read MoreBioStock article: Cyxone’s Covid-19 trial with Rabeximod initiated in Europe
BioStock published an article on 22 January 2021 about Cyxone, which can be read in full below. Last week, the biotech company Cyxone announced that the first patient has been screened in the phase II trial with their candidate...
Read MoreBioStock article: Regulatory approval and up-listing for Cyxone
BioStock published an article on 14 December 2020 about Cyxone, which can be read in full below. Activity is high in Cyxone. The biotechnology company recently received approval to start a phase II study in Poland with Rabeximod in...
Read MoreCyxone’s presentation at BioStock Life Science Summit 18 November now published
Cyxone’s CEO Tara Heitner presented the company at BioStock Life Science Summit on 18 November 2020. Click here to see the video. Contact Tara Heitner, CEO Tel: +46 70 781 88 08 Email: tara.heitner@cyxone.com Adelgatan 21 211 22 Malmö,...
Read MoreBioStock article: Cyxone attracts funding and files for new patents
BioStock published an article on 13 November 2020 about Cyxone, which can be read in full below. In a short period of time, biotech company Cyxone has secured some 40 MSEK to fund the phase II study of Rabeximod...
Read MoreBioStock article: Cyxone comments positive toxicological results
BioStock published an article on 10 November 2020 about Cyxone, which can be read in full below. Recently, biotech company Cyxone announced positive results from completed toxicological studies of the drug candidate Rabeximod for treatment of rheumatoid arthritis. The...
Read MoreCyxone ranked top 5 by Startus Insights
Startus Insights ranks Cyxone as one of five top specialty pharma startups impacting the industry. Link to Startus Insights ranking
Read More